methyl 2-(4-aminobutoxy)-6-hydroxybenzoate hydrochloride salt

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 2-(4-aminobutoxy)-6-hydroxybenzoate hydrochloride salt
• 英文别名: 2-(4-amino-butoxy)-6-hydroxy-benzoic acid methyl ester hydrochloride；Methyl 2-(4-aminobutoxy)-6-hydroxybenzoate hydrochloride；methyl 2-(4-aminobutoxy)-6-hydroxybenzoate;hydrochloride
• 化学式: C₁₂H₁₇NO₄*ClH
• 分子量: 275.732
• InChiKey: LCUOUWVSVACLPD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.42
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  83.4
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  methyl 2-(4-aminobutoxy)-6-hydroxybenzoate hydrochloride salt 在 1-羟基苯并三唑 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 三乙胺 、 三氟乙酸 、 间苯二酚 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 7.0h， 生成 methyl 2-[4-({N-[(allyloxy)carbonyl]-4-[(carboxycarbonyl)(2-carboxyphenyl)amino]-L-phenylalanyl}amino)butoxy]-6-hydroxybenzoate
  参考文献：
  名称：

  Selective Protein Tyrosine Phosphatase 1B Inhibitors:  Targeting the Second Phosphotyrosine Binding Site with Non-Carboxylic Acid-Containing Ligands

  摘要：

  Protein tyrosine phosphatase (PTPase) 1B (PTP1B) has been implicated as a key negative regulator of both insulin and leptin signaling cascades. We identified several salicylic acid-based ligands for the second phosphotyrosine binding site of PTP1B using a NMR-based screening. Structure-based linking with a catalytic site-directed oxalylarylaminobenzoic acid-based pharmacophore led to the identification of a novel series of potent PTP1B inhibitors exhibiting 6-fold selectivity over the highly homologous T-cell PTPase (TCPTP) and high selectivity over other phosphatases.

  DOI：

  10.1021/jm034088d
• 作为产物：
  描述：

  2,6-二羟基苯甲酸甲酯 在 盐酸 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 4.5h， 生成 methyl 2-(4-aminobutoxy)-6-hydroxybenzoate hydrochloride salt
  参考文献：
  名称：

  Selective Protein Tyrosine Phosphatase 1B Inhibitors:  Targeting the Second Phosphotyrosine Binding Site with Non-Carboxylic Acid-Containing Ligands

  摘要：

  Protein tyrosine phosphatase (PTPase) 1B (PTP1B) has been implicated as a key negative regulator of both insulin and leptin signaling cascades. We identified several salicylic acid-based ligands for the second phosphotyrosine binding site of PTP1B using a NMR-based screening. Structure-based linking with a catalytic site-directed oxalylarylaminobenzoic acid-based pharmacophore led to the identification of a novel series of potent PTP1B inhibitors exhibiting 6-fold selectivity over the highly homologous T-cell PTPase (TCPTP) and high selectivity over other phosphatases.

  DOI：

  10.1021/jm034088d

文献信息

• Selective protein tyrosine phosphatatase inhibitors
  申请人：——

  公开号：US20020169157A1

  公开（公告）日：2002-11-14

  Compounds of formula (I) 1 or therapeutically acceptable salts thereof, are selective protein tyrosine kinase-B (PTP1B) inhibitors. Preparation of the compounds, compositions containing the compounds, and treatment of disorders using the compounds are disclosed.

  式（I）1的化合物或其治疗上可接受的盐是选择性蛋白酪氨酸激酶B（PTP1B）抑制剂。揭示了该化合物的制备、含有该化合物的组合物以及使用该化合物治疗疾病的方法。
• [EN] SELECTIVE PROTEIN TYROSINE PHOSPHATASE INHIBITORS<br/>[FR] INHIBITEURS SELECTIFS DE PROTEINE TYROSINE PHOSPHATASE
  申请人：ABBOTT LAB

  公开号：WO2003020688A1

  公开（公告）日：2003-03-13

  Compounds of formula (I) or therapeutically acceptable salts thereof, are selective protein tyrosine kinase-B (PTP1B) inhibitors. Preparation of the compounds, compositions containing the compounds, and treatment of disorders using the compounds are disclosed.

  式(I)的化合物或其治疗上可接受的盐是选择性的蛋白酪氨酸激酶-B (PTP1B) 抑制剂。本文披露了该化合物的制备、含有该化合物的组合物以及使用该化合物治疗疾病的方法。
• Inhibitors of proteins that bind phosphorylated molecules
  申请人：Combs P. Andrew

  公开号：US20050272778A1

  公开（公告）日：2005-12-08

  The present invention provides compounds that can modulate the activity of a target protein, such as a phosphatase, that selectively binds phosphorylated peptides or proteins. The present compounds can be useful in treating diseases or disorders, including, for example, diabetes and obesity, that are connected directly or indirectly to the activity of the target protein.

  本发明提供了可以调节目标蛋白活性的化合物，例如选择性结合磷酸化肽或蛋白质的磷酸酶。这些化合物可以用于治疗与目标蛋白活性直接或间接相关的疾病或障碍，例如糖尿病和肥胖症。
• WO2006/55525
  申请人：——

  公开号：——

  公开（公告）日：——
• US6972340B2
  申请人：——

  公开号：US6972340B2

  公开（公告）日：2005-12-06